Other languages Catalyst Pharmaceuticals, Inc.

Equities

CPRX

US14888U1016

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
14.72 ^USD	-2.00%		-1.14%	-12.43%

Apr. 10	Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	MT
Apr. 04	Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera dans les chiffres noirs en 2023	Apr. 25
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	Apr. 10
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	Mar. 28
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	Mar. 14
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	Mar. 14
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	Mar. 13
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	Mar. 13
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	Mar. 07
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	Feb. 29
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Catalyst Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Catalyst Pharmaceuticals Seeks Acquisitions	Jan. 10
Catalyst Pharmaceuticals Raises $140.1 Million From Share Offering	Jan. 09
Top Stories at Midday: December US Nonfarm Payrolls Rise; ISM US Services Index Falls; CVS Names Finance Chief; Tesla to Recall Vehicles in China; Catalyst Prices Stock Offering	Jan. 05
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	Jan. 05
Catalyst Pharmaceuticals Prices $150 Million Share Offering	Jan. 05
Catalyst Pharmaceuticals Unveils $150 Million Equity Offering -- Shares Slump After Hours	Jan. 04
Dydo Group Unit Files New Drug Application for Autoimmune Disease Treatment Candidate	Dec. 19
Catalyst Pharmaceuticals Partner Submits New Drug Application for Neuromuscular Disorder Treatment in Japan	Dec. 18
Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma	Dec. 18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Catalyst Pharmaceuticals, Inc: Optimistic scenario

March 06, 2023 at 10:44 am EST